TP53INP2 and Alzheimer disease: Dextromethorphan (NMDA receptor agonist) is an established antitussive drug that targets TP53INP2 and a clinical trial (www.clinicalTrials.gov ID: NCT01584440) is already running to test if Dextromethorphan can be used as a drug for treating AD.